Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video) - 2Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- 3International issues on the agenda as Frances's Macron visits China
- 4Israel faces widespread condemnation as NGO ban comes into effect
- 55 things for parents to know about changes to kids vaccine schedule
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- Experience Sports in Dubai: A Daredevil's Aide
- Vinicultural Investigation: A Survey of \Enjoying Fine Vintages\ Wine sampling
- How food assistance programs can feed families and nourish their dignity
- Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- Merz: 80% of Syrians in Germany should return in three years
